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Abstract
Background: High activity of cysteine proteases such as legumain and the cathepsins have been shown to
facilitate growth and invasion of a variety of tumor types. In breast cancer, several recent studies have indicated
that loss of the cysteine protease inhibitor cystatin E/M leads to increased growth and metastasis. Although
cystatin E/M is normally expressed in the skin, its role in cysteine protease regulation and progression of malignant
melanoma has not been studied.
Methods: A panel of various non-melanoma and melanoma cell lines was used. Cystatin E/M and C were analyzed
in cell media by immunoblotting and ELISA. Legumain, cathepsin B and L were analyzed in cell lysates by
immunoblotting and their enzymatic activities were analyzed by peptide substrates. Two melanoma cell lines
lacking detectable secretion of cystatin E/M were transfected with a cystatin E/M expression plasmid (pCST6), and
migration and invasiveness were studied by a Matrigel invasion assay.
Results: Cystatin E/M was undetectable in media from all established melanoma cell lines examined, whereas
strong immunobands were detected in two of five primary melanoma lines and in two of six lines derived from
patients with metastatic disease. Among the four melanoma lines secreting cystatin E/M, the glycosylated form (17
kD) was predominant compared to the non-glycosylated form (14 kD). Legumain, cathepsin B and L were
expressed and active in most of the cell lines, although at low levels in the melanomas expressing cystatin E/M. In
the melanoma lines where cystatin E/M was secreted, cystatin C was generally absent or expressed at a very low
level. When melanoma cells lacking secretion of cystatin E/M were transfected with pCST6, their intracellular
legumain activity was significantly inhibited. In contrast, cathepsin B activity was not affected. Furthermore, invasion
was suppressed in cystatin E/M over-expressing melanoma cell lines as measured by the transwell Matrigel assay.
Conclusions: These results suggest that the level of cystatin E/M regulates legumain activity and hence the
invasive potential of human melanoma cells.
Background
Cystatins are endogenous inhibitors of cysteine pro-
teases that form reversible, high-affinity complexes with
their target proteases [1]. Loss of cystatin function
results in deregulated activity of cysteine proteases and
may lead to a variety of disorders, including chronic
inflammatory reactions [2], faulty differentiation in epi-
dermis [3], and tumor malignancy [4]. Cystatin E/M was
originally identified as a cysteine protease inhibitor
down-regulated in metastatic versus primary breast
cancer cells [5,6], and subsequent studies have indicated
that loss of cystatin E/M expression during the progres-
sion of breast cancer, glioma and lung cancer results
from epigenetic silencing of the CST6 gene [7-11].
Restoration of cystatin E/M expression in breast cancer
reduces growth, migration, and Matrigel invasion in
vitro [12], as well as tumor growth and metastatic bur-
den in vivo [13]. In glioma, expression of cystatin E/M
inhibited cell motility and invasion in vitro [14]. Overall,
these studies suggest a tumor suppressor function for
this protease inhibitor.
Cystatin E/M exerts its inhibitory effects on two
families of cysteine proteases, the papain-like cysteine
proteases, including the cathepsins B, L, and V [15,16],
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and the asparaginyl endopeptidase (AEP) legumain,
through two distinct binding sites [17]. The cathepsins
are located in lysosomal compartments but may also be
secreted to degrade extracellular matrix components
[18]. Cathepsins B and L have been implicated in inva-
sion and metastasis [19-21] and elevated levels have
been observed in a variety of cancer types [22-24]. In
melanoma, cathepsin B and L activities are increased
relative to normal skin [25], and both the cysteine pro-
teases conferred a metastatic phenotype [26,27]. Legu-
main is primarily a lysosomal enzyme, however, it has
also been found on the cell surface and in membrane-
associated vesicles concentrated along the invadopodia
of tumor cells [28]. It is highly expressed in several can-
cer types including colon, prostate and breast cancer,
and increased levels have been observed relative to adja-
cent non-neoplastic tissue in colorectal cancer [29].
Cells over-expressing legumain exhibit increased inva-
siveness both in vitro and in vivo [28], possibly attribu-
ted to the ability of legumain to activate proMMP-2
[28,30].
Our initial interest in cystatin E/M arose from micro-
array studies comparing the gene expression profiles of
primary and metastatic melanoma [31], where expres-
sion of the cystatin E/M gene (CST6) was observed in
normal skin and thin primary tumors, but not in thicker
primaries or metastatic disease. This led us to hypothe-
size that cystatin E/M expression may be lost during the
initial phases of melanoma tumor progression. To study
the role of this protease inhibitor further, we utilized
low-passage cell lines established from both primary and
metastatic patient lesions. Cell lines were screened for
secretion of cystatin E/M and C, as well as expressions
of legumain, cathepsin B and L. We found that cystatin
E/M, legumain, cathepsin B and L were expressed in
several of these melanoma cell lines and that over-
expression of cystatin E/M resulted in inhibition of legu-
main activity and decreased invasiveness.
Methods
Cell lines
Cell lines were established from freshly procured sam-
ples from patients with primary (MCC5, MCC13,
MCC70, MCC80A) or metastatic (MCC11, MCC35,
MCC52, MCC57, MCC69B, and MCC72) malignant
melanoma at Moffitt Cancer Centre (MCC; Tampa, FL,
USA) using standard in vitro cell culturing techniques
[31]. The cell line DK928 was established from a patient
with primary melanoma at the Mitchell Cancer Institute,
University of South Alabama (Mobile, AL, USA). The
following cell lines were obtained from patients with
malignant melanoma treated at the Surgery Branch,
Division of Clinical Sciences, National Cancer Institute
(National Institutes of Health, Bethesda, MD, USA);
624.38 [32], 1495 [33], and 2139 (unpublished). The
uveal melanoma cell line 92.1 was generously provided
by Martine Jager (Leiden University Medical Centre,
The Netherlands; [34]). The breast carcinoma cell line
MA11 was established from bone marrow aspirate from
a patient with lobular carcinoma [35], and the mela-
noma cell line WM239 was obtained from Meenhard
Herlyn (The Wistar Institute, Philadelphia, PA, USA).
A375 and SK-MEL-28 (both from malignant melanoma),
DU145 (prostate carcinoma), HCT-116 (colorectal carci-
noma), MCF7 (breast carcinoma) and MCF10A (non-
tumorigenic mammary epithelial) were obtained from
the American Type Culture Collection (ATCC, Rock-
ville, MD, USA), and the human dermal fibroblasts
(HDF) were purchased from ScienceCell Research Labs
(San Diego, CA, USA). Most of the cells were grown in
RPMI 1640 (BioWhittaker, Verviers, Belgium) with 10%
FBS (Hyclone, Logan, Utah, USA), 1% Glutamax (Invi-
trogen, Carlsbad, CA, USA), and 1% Penicillin-strepto-
mycin (BioWhittaker). Exceptions were DU145, HCT-
116 and HDF which were grown in DMEM (BioWhit-
taker) with 10% FBS, 1% Glutamax, and 1% Penicillin-
streptomycin, and MCF10A which was maintained in
DMEM/F12 (BioWhittaker) containing 5% horse serum
(Gibco Life Tech., Gaithersburg, MD, USA), 1 μg/ml
insulin (Sigma, St Louis, MO, USA), 20 ng/ml EGF (BD
Collaborative Research, Bedford, MD, USA), 1% Gluta-
max, and 1% Penicillin-streptomycin. The cells were
passed approximately twice a week using trypsin/EDTA
(BioWhittaker). In addition, the human keratinocyte cell
line HaCaT [36] was cultured in Keratinocyte-SFM
(Invitrogen Life Technologies) supplemented with 0.2
ng/ml human recombinant epidermal growth factor, 30
μg/ml bovine pituitary extract, and Penicillin-streptomy-
cin. Further, whole cell lysates of human melanocytes
(Mel) were kindly provided by Léon van Kempen (Dept.
of Pathology, Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands).
Transfections
Cells (A375 and MCC11) were seeded at 5 × 105 per
well in a 6-well plate approximately 24 h prior to trans-
fection. Transfections were performed using Lipofecta-
mine 2000 (Invitrogen) following the manufacturer’s
protocol. Briefly, the transfection mixture contained a
total of 4 μg plasmid (pTracer empty vector or pTracer
containing a full-length human cystatin E/M cDNA
(pCST6; kindly provided by Daniel Keppler, College of
Pharmacy, Touro University-California, Vallejo, CA,
USA)) and 10 μl Lipofectamine 2000 in 500 μl DMEM
without FBS or antibiotics. This mixture was added to
each well containing 2 ml DMEM with 10% FBS and no
antibiotics. The following day, the transfection mixture
was removed and the appropriate medium for experi-
ments was added.
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Preparation of whole cell extracts for immunoblotting
Cells were washed 3 times with ice cold phosphate-buf-
fered saline (PBS), scraped into PBS and pelleted by cen-
trifugation at 2,500 × g for 5 min at 4°C. Pellets were
resuspended in RIPA triple detergent lysis buffer (50
mM Tris (pH 8.0), 150 mM NaCl, 0.02% sodium azide,
0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 1 mM
PMSF, 2 μg/ml leupeptin, 2 μg/ml aprotinin, and 2 μg/
ml pepstatin), and incubated on ice for 30 min. Lysates
were centrifuged at 15,000 × g for 30 min. Supernatants
were collected and protein concentration was deter-
mined using the BCA protein assay kit (Pierce, Rock-
ford, IL, USA).
Preparation of whole cell extracts for enzymatic activities
Cells were seeded at 5 × 105 per well in 6-well plates,
and the following day the medium was replaced with 1
ml fresh medium without serum. After 24 h, adherent
cells were washed 3 times in PBS before adding lysis
buffer containing 100 mM sodium citrate, 1 mM diso-
dium EDTA, 1% n-octyl-b-D-glucopyranoside, pH 5.8.
Cell harvesting was assisted by a cell scraper and the
collected lysates were frozen at -70°C. Following three
cycles of freezing and thawing, the cell lysates were cen-
trifuged at 10,000 × g for 5 min and the supernatants
were applied to enzymatic activity analyses. Protein con-
centrations in the lysates were measured by the proce-
dure described by Bradford [37], and performed
according to the manufacturer (Bio-Rad Laboratories,
Hercules, CA, USA) in a microplate reader measuring
absorbance at 595 nm. Bovine serum albumin (Pierce)
was used as a standard and all measurements were per-
formed in triplicate.
TCA precipitation of secreted proteins
The day following transfection or seeding in a 6-well
plate, the medium was replaced with 1 ml fresh medium
without serum. The conditioned medium was collected
48 h later and passed through a 0.45 μm filter. To preci-
pitate secreted proteins, 0.5 ml 40% trichloroacetic acid
(TCA) was added to 0.5 ml supernatant. Samples were
vortexed thoroughly and incubated on ice for 1 h. Sam-
ples were spun at 14,000 × g for 30 min and superna-
tant was discarded. Pellets were re-suspended in ice-
cold acetone using sonication and samples were incu-
bated overnight at -20°C. Samples were washed twice by
spinning at 14,000 × g for 5 min and re-suspension in
acetone. Pellets were allowed to air dry for approxi-
mately 2 min and re-suspended in RIPA lysis buffer for
SDS-PAGE.
SDS-PAGE and immunoblotting
Whole cell extract (25 μg total protein), recombinant
human legumain (5 ng; R&D Systems, MN, USA; 2199-
CY) or pellets from TCA precipitation dissolved in
RIPA lysis buffer were supplemented with Laemmli
SDS-PAGE sample buffer (Invitrogen) and boiled at
100°C for 5 min. Samples were applied to 4-12% gradi-
ent gels in 2-(N-morpholino) ethanesulfonic acid (MES)
buffer for SDS-PAGE (Invitrogen). Proteins were trans-
ferred to a 0.22 μm PVDF membrane (Millipore Cor-
poration, Bedford, MA, USA) using the Xcell sure-lock
mini-cell (Invitrogen) according to the manufacturers
instructions. Following transfer, the membrane was
blocked by incubation for one hour at room tempera-
ture in blocking buffer (TBS containing 5% non-fat dry
milk and 0.1% Tween). Membranes were probed over-
night at 4°C with primary antibody dissolved in blocking
buffer at the following concentrations: cystatin E/M goat
polyclonal (1:500; R&D Systems, AF1286), cystatin C
goat polyclonal (1:1000; R&D Systems; AF1196), legu-
main goat polyclonal (1:1000; R&D Systems; AF2199),
cathepsin B rabbit polyclonal (1:10,000; Calbiochem, San
Diego, CA, USA), cathepsin L goat polyclonal (1:500;
R&D Systems; AF952), a-tubulin mouse monoclonal
(1:5000; Calbiochem) and b-actin mouse monoclonal
(1:5000; Sigma). Membranes were washed twice for 5-10
min with washing buffer (TBS with 0.1% Tween). The
membranes were subsequently probed with secondary
antibody dissolved in blocking buffer at the following
concentrations for one hour: horseradish peroxidase-
conjugated goat anti-rabbit (1:5000), rabbit anti-goat
(1:5000), or rabbit anti-mouse (1:5000) antibodies
(DakoCytomation, Glostrup, Denmark). Subsequently,
membranes were washed three times with washing buf-
fer for 20 min and signals were developed with Super
Signal West Dura Extended Duration Substrate (Pierce)
according to the manufacturer’s instructions, and visua-
lized on either Medical X-ray films (Kodak, Rochester,
NY) or the digital image station IS2000 (Kodak).
The immunobands visualized using a digital image
station were quantified in the related software MI
v.4.0.1 (Kodak), and those from X-ray films were
scanned in a calibrated densitometer GS-800 (Bio-Rad)
and quantified in the related software QuantityOne
v.4.6.5 (Bio-Rad). All measured quantities were normal-
ized using the corresponding loading control (a-tubulin)
for each lane.
ELISA
Serum-free conditioned media was collected after 48 h
and passed through a 0.45 μm filter. The media was
analyzed utilizing published ELISA procedures to deter-
mine the amount of cystatin C [38], cystatin E/M [39]
and cystatin F [40] secreted by the cells. In addition, a
specific ELISA was established for cystatin D using
methods and materials described earlier for a mouse
cystatin C ELISA [41]. Briefly, the IgG fraction of a
high-titer polyclonal rabbit antiserum against recombi-
nant human cystatin D [42] not showing cross-reactivity
against cystatins A, B, C, D, E/M, F, S, SN and kinino-
gen was used for construction of a double sandwich
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ELISA. Wells in polystyrene microplates (MaxiSorp;
Nunc, Copenhagen, Denmark) were coated with the IgG
fraction as catching antibody. Sample or isolated recom-
binant cystatin D [42] in dilutions from 0.2 to 100 ng/
mL, was added to the wells. A portion of specific anti-
bodies, affinity purified from the same IgG fraction of
the anti-serum was biotinylated [43] and used as detect-
ing antibody. Bound cystatin D was quantified using a
streptavidin-horseradish peroxidase conjugate (Amer-
sham Biosciences, Buckinghamshire, UK) and the color
reaction with 2,2-azino-di-(3-ethyl-benzothiazolin-sulfo-
nate) (Sigma) to detect peroxidase activity as absorbance
at 405 nm.
Matrigel invasion assay
Cells were seeded at 2 × 105 per well in 6-well plates
and transfected with pCST6 or empty vector (pTracer)
as described above. The following day, the transfection
medium was removed and cells were grown in fresh
RPMI (with 10% FBS) for approximately 6 hours. This
medium was removed and cells were grown in RPMI
(10% FBS) supplemented with [methyl-3H] thymidine
(Amersham) for 24 h. Cells were detached with trypsin
and 5 × 104 [3H]-labeled cells in 100 μl medium were
added to each well in a 24-transwell permeable plate
(8.0 μm polycarbonate membrane, 6.5 mm insert; Corn-
ing Incorporated, Corning, NY, USA) coated with Matri-
gel basement membrane matrix (1:60 dilution; BD
Biosciences, San Jose, CA, USA). For migration studies
the wells were left uncoated. The bottom wells received
600 μl medium with the same concentration of serum
as the top well, either 1% or 10% FBS. Cells were
removed from the upper and lower sides of the filter
after 72 h incubation and [3H]-thymidine was counted
in a liquid scintillation analyzer (Wallac Oy, Turku, Fin-
land). The ratio of the counts obtained from the bottom
versus total counts from both sides was used to deter-
mine migration and invasiveness.
Measurements of proteolytic activities
Legumain activity was measured by cleavage of the sub-
strate Z-Ala-Ala-Asn-NHMec (Department of Biochem-
istry, University of Cambridge, UK) as previously
described [44,45]. Cell lysate (20 μl) was added to black
96-well microplates (No. 3915; Costar, Corning, NY,
USA). After the addition of 100 μl buffer and 50 μl sub-
strate solution (final concentration 10 μM), a kinetic
measurement based on increase in fluorescence over 10
min was performed. Temperature was kept at 30°C and
all measurements were performed in triplicate. Cathe-
psin B activity was measured in a similar manner except
for the use of the substrate Z-Arg-Arg-NHMec (20 μM;
Bachem AG, Bubendorf, Switzerland) and a buffer sys-
tem described elsewhere [46,47]. Cathepsin L activity
was measured using the substrate Z-Phe-Arg-NHMec
(40 μM; Bachem AG) in the presence of the cathepsin
B-specific inhibitor CA074 (0.25 μM; Sigma) as pre-
viously reported [46], with and without the addition of
the cathepsin L-specific inhibitor Z-Phe-Tyr(t-Bu)-diazo-
methylketone (2.5 μM; Calbiochem).
Inhibitory activity towards legumain was measured in
the culture media from all the cell lines and from the
pCST6-transfected cells (A375 and MCC11). Inhibitory
activity was evaluated by measuring the residual enzyme
activity in a preparation of legumain after the addition
of conditioned media. As a source of legumain, homoge-
nized rat kidney was applied to a cation exchange col-
umn (Resource S, 1 ml, Amersham Biosciences) and
eluted with a gradient of sodium chloride as described
previously [48]. Peak legumain activity eluted at about
0.3 M NaCl and this partially purified legumain fraction
was used as an enzyme source together with the sub-
strate Z-Ala-Ala-Asn-NHMec. Legumain (20 μl) and
media samples (17 μl) were added 83 μl buffer and incu-
bated for 10 min, before 50 μl substrate solution was
added (10 μM final concentration). Activity of the legu-
main preparation alone was used as positive control and
the residual legumain activity after addition of condi-
tioned media was measured and degree of inhibition cal-
culated for each cell media.
Statistical analysis
Data are shown as the mean ± standard error of the
mean (SEM). Statistical significance of the Matrigel
invasion assays was evaluated using the two-tailed Stu-
dent’s t-test, whereas two-way ANOVA was used to
evaluate protease activities.
Results
Cystatin E/M expression in malignant melanoma cell lines
Although it is known that cystatin E/M is secreted by
keratinocytes and is present in the skin [49], little is
known concerning its expression in melanocytes or mel-
anoma cells. To study this, we analyzed a panel of low
passage cell lines derived from primary and metastatic
lesions in addition to well-established melanoma cell
lines. Conditioned media from an equal number of cells
was collected 48 h after changing to serum-free media.
Proteins in the supernatants were TCA-precipitated and
examined for cystatin E/M and C expressions using
immunoblotting. Several non-melanoma controls
secreted cystatin E/M, including DU145, HCT-116 and
MA11, and nearly equal amounts of unglycosylated (14
kD) and glycosylated (17 kD) forms were found (Fig.
1A, upper panels). Notably, in control cells derived from
the skin, no cystatin E/M was secreted from human der-
mal fibroblasts (HDF), whereas HaCaT keratinocytes
predominately secreted the non-glycosylated 14 kD
cystatin E/M form. In contrast, the protease inhibitor
was undetectable in media from all established mela-
noma cell lines examined, whereas strong immunobands
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Figure 1 Cystatin E/M and C secretions from various cell lines: Common laboratory non-melanoma and established laboratory melanoma
cell lines (top), and primary and metastatic melanoma cell lines established from patients, as well as skin control (bottom). (A) Equal amounts of
serum free media were collected from 5 × 105 cells 48 h after changing from ordinary growth media and secreted proteins were concentrated
by TCA-precipitation and subjected to SDS-PAGE and immunoblotting. The filters were stained with a cystatin E/M-specific (upper panels) or a
cystatin C-specific (lower panel) antibody, respectively. (B) Inhibitory activity against legumain was measured in the conditioned media as
residual legumain activity. A partially purified legumain fraction from rat kidney was mixed with conditioned media and the ability to cleave the
substrate Z-Ala-Ala-Asn-NHMec was measured by fluorometry. Control bar (100%) represents activity in the rat legumain fraction without
addition of conditioned media.
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were detected in two of the five primary melanoma lines
(MCC13 and MCC70), and in two of the six lines
derived from patients with metastatic disease (MCC57
and MCC72). Among the four melanoma lines secreting
cystatin E/M, the glycosylated form (17 kD) was predo-
minant compared to the non-glycosylated form (14 kD)
in media from all but one cell line (MCC70).
Another cysteine protease inhibitor, cystatin C, was
detected as one band (15 kD) in media from most of
the cell lines examined (Fig. 1A, lower panels). However,
in the melanoma lines where cystatin E/M was secreted,
cystatin C was generally absent (MCC13, MCC57 and
MCC72) or expressed at a very low level (MCC70).
None of the cystatins were observed in the primary
uveal melanoma cell line 92.1.
ELISA was used to quantify cystatin E/M and C in the
conditioned media (Table 1). Among all the melanoma
cell lines studied, cystatin E/M was only detected in the
primary line MCC70 (0.28 ng/ml), whereas several of
the non-melanoma lines displayed detectable levels
(0.05-0.55 ng/ml; Table 1). Linear regression analyses
showed a positive correlation between cystatin E/M
levels measured by ELISA versus both the non-glycosy-
lated (p < 0.0001) and the glycosylated (p = 0.0014)
form of cystatin E/M on immunoblots after band inten-
sities were scored 0-3 (exact quantification was difficult
due to lack of representative loading controls for media
samples). In addition, cystatin C was detected in media
from all the cell lines analyzed except MCC13 (Table 1),
with a positive correlation (p < 0.0001) between cystatin
C as measured by ELISA and intensities of the immuno-
bands (scored 0-3). Of other cystatins, cystatin F was
only detected in media from MCC35 cells (5.6 ng/ml),
whereas no detectable levels of cystatin D were observed
in media from any of the cell lines.
Furthermore, the cellular levels of both cystatin E/M
and C have been investigated by immunoblotting of cell
lysates from all the cell lines included. No immuno-
bands were obtained indicating that the cellular levels of
both cystatins were below the level of detection (data
not shown).
Inhibition of legumain by conditioned melanoma media
The conditioned media from all cell lines was analyzed
by fluorometry for their ability to inhibit the activity of
a partially purified legumain fraction from rat kidney
(Fig. 1B). Legumain inhibition was measured as residual
legumain activity after addition of conditioned media to
a fixed amount of purified legumain. Legumain activity
in the enzyme preparation without addition of media
was used as control (100% activity). Of the melanoma
lines, MCC13, MCC57 and MCC72 showed the lowest
residual legumain activity and thus highest inhibitory
capacity. Cystatin E/M levels as detected by immuno-
blotting were scored (0-3) and a correlation analyzes
performed, showing a statistically significant positive
correlation in the whole cell panel (p = 0.0012) when
comparing the level of cystatin E/M and the ability to
inhibit rat legumain by the same cell media sample. In
addition, inhibition of papain activity was measured
similarly by cleavage of the substrate Z-Phe-Arg-
NHMec with or without adding culture media from all
cell lines studied (data not shown). Linear regression
analyses showed that inhibition of papain correlated sta-
tistically significant with the cystatin C levels measured
by ELISA (p = 0.0256), but not with the level of cystatin
E/M.
Cysteine protease expressions and activities in melanoma
Although the activities of cathepsin B and L in mela-
noma and other tumor types are well documented, the
expression and activity of legumain in melanoma is rela-
tively unknown. To determine expression of legumain,
cathepsin B and L, whole cell lysates were prepared
Table 1 Secretion of cystatin E/M and C into cell media
measured by ELISA
Cell line Cystatin E/M
(ng/ml)
Cystatin C
(ng/ml)
Non-melanoma
DU145 0.11 2.7
HCT-116 0.55 8.0
HDF n.d.1 7.4
MA11 0.33 2.0
MCF7 n.d. 10.2
MCF10A 0.05 11.2
Established melanoma
92.1 n.d. 6.0
624.38 n.d. 10.1
1495 n.d. 7.0
2139 n.d. 7.5
A375 n.d. 8.8
SK-MEL-28 n.d. 9.6
WM239 n.d. 21.4
Primary melanoma
MCC5 n.d. 6.3
MCC13 n.d. n.d.
MCC70 0.28 6.3
MCC80A n.d. 6.6
DK928 n.d. 9.9
Metastatic melanoma
MCC11 n.d. 7.5
MCC35 n.d. 18.8
MCC52 n.d. 18.4
MCC57 n.d. 1.9
MCC69b n.d. 13.3
MCC72 n.d. 1.5
1n.d.: not detectable
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from the same panel of cell lines as used for cystatin E/
M analysis (Fig. 1) following growth in ordinary media
for 24 h. Immunoblotting was performed and two mole-
cular bands for legumain were observed in most of the
cell lines examined (Fig. 2, upper panels). The highest
molecular weight form migrated at approximately 52 kD
and represents prolegumain, while the smaller band of
approximately 36 kD represents the active form. Three
cell lines had only weak expression of the 36 kD band
(MCC13, MCC57 and MCC72). Interestingly, these
were the same cell lines that predominantly secreted the
glycosylated form of cystatin E/M (17 kD) and showed
the highest inhibitory activity against exogenously added
legumain (Fig. 1).
Both cathepsin B and L were detected in most of the
cell lines, except those predominantly secreting the gly-
cosylated form of cystatin E/M (MCC13, MCC57 and
MCC72; Fig. 2, middle panels). For cathepsin B, most of
the positive melanoma lines expressed the 25 kD mole-
cular weight form, whereas a few cell lines also showed
lower levels of the 30 kD form. One cell line (624.38)
expressed only low levels of the 30 kD form. Cathepsin
L was generally expressed as three forms with molecular
weights of 38, 30 and 25 kD, respectively. Interestingly,
those melanoma cell lines from patients showing a
strong expression of the 36 kD active legumain form,
seemed to have a stronger expression of the 25 kD
active cathepsin L form compared to the 30 kD form,
although not statistically significant. This relationship
also seemed to be expressed in HaCaT keratinocytes but
not in the melanocyte (Mel) control (Fig. 2).
In addition, legumain, cathepsin B and L activities in
the cell lysates were measured by their ability to cleave
peptide substrates (Fig. 3). Linear regression analysis of
the whole group of cell lines revealed a positive correla-
tion between legumain activity (Fig. 3A) and expression
of the putative active 36 kD form (Fig. 2) and between
cathepsin B activity (Fig. 3B) and expression of the 25
kD form (Fig. 2) (p = 0.0141 and 0.0351, respectively),
as quantified using densitometric scanning of the immu-
noblots. In contrast, there were no statistical correlation
between immunobands (Fig. 2) and activity (Fig. 3C) of
cathepsin L. Two cell lines (HDF and 2139) showed par-
ticularly high cathepsin L activity (Fig. 3C), also reflected
in strong immunobands (Fig. 2). Furthermore, legumain
activity was analyzed in conditioned cell media but no
active secreted legumain was detected.
Over-expression of cystatin E/M suppressed legumain
activity in melanoma
To further investigate the relationship between cystatin
E/M and legumain, two cell lines with no detectable
levels of secreted cystatin E/M (A375 and MCC11; Fig.
1A; Table 1) and low inhibitory activity against legumain
in the culture media (shown as high residual legumain
activity, Fig. 1B) were utilized. A375 is a commonly
used melanoma cell line, with intermediate expression
of the 36 kD form of legumain (Fig. 2). MCC11 is a
low-passage melanoma line established from a patient’s
lymph node metastases showing a high level of the 36
kD form of legumain (Fig. 2). These cell lines were
transfected with the cystatin E/M expression plasmid
pCST6 and the following day the transfection media
was changed to serum-free media. Conditioned media
and cell lysates were collected 24 h thereafter, and cysta-
tin E/M expression was analyzed by immunoblotting.
Whereas no immuno-reactive bands were found in vec-
tor-transfected cells, substantial levels of both cystatin
E/M forms (14 and 17 kD) were observed both in condi-
tioned media (Fig. 4A, upper panels) and in lysates (Fig.
4A, middle panels) from pCST6-transfected cells. No
active legumain was found in conditioned media. The
conditioned media was also examined for the ability to
inhibit legumain activity using the partially purified
legumain fraction from rat kidney as enzyme source
(Fig. 4B). Media from both pCST6-transfected cell lines
(closed bars) significantly inhibited legumain activity
compared to empty vector-transfected controls (open
bars). Media from transfected A375 cells almost comple-
tely inhibited (97%; p < 0.0001) the activity of the rat
legumain fraction, whereas media from transfected
MCC11 inhibited the enzyme activity by 22% (p =
0.002).
Legumain activity in the corresponding cell lysates
from the pCST6-transfections was also measured, and
the activity in both A375 and MCC11 was significantly
decreased compared to controls (p < 0.0001 and p =
0.0012, respectively; Fig. 4C). A375 cells had a lower
basal level of legumain activity than MCC11, which is
reflected in the empty vector-transfected cells (control;
Fig. 4C, open bars). Over-expression of cystatin E/M
decreased the intracellular legumain activity by 62% and
25% in A375 and MCC11, respectively (closed bars). For
comparison, there were no differences between the
activities of cathepsin B in the same lysates when com-
paring control versus pCST6-transfected cells (not
shown). Further, immunoblotting and densitometric
scanning of the 36 kD legumain band in lysates from
pCST6-transfected cells reflected the down-regulation of
enzyme activity (not shown).
Over-expression of cystatin E/M decreased invasiveness
of metastatic melanoma
Although it has been reported that cystatin E/M is cap-
able of suppressing invasion of breast cancer [12,13], its
ability to inhibit melanoma progression has not been
investigated. To determine the contribution of cystatin
E/M to the suppression of invasion, the pCST6-trans-
fected cell lines A375 and MCC11 were examined for
their ability to migrate through a Matrigel-coated filter
Briggs et al. BMC Cancer 2010, 10:17
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Figure 2 Legumain, cathepsin B and L expressions in various cell lines: Common laboratory non-melanoma and established laboratory
melanoma cell lines (top), and primary and metastatic melanoma cell lines established from patients, as well as skin controls (bottom). Whole
cell extracts were collected 24 h after seeding and equal amounts of total protein (25 μg) were used for SDS-PAGE and immunoblotting. The
filters were stained with a legumain-specific (upper panels), cathepsin B- and L-specific (middle panels) or a-tubulin specific (lower panels)
antibody, respectively.
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Figure 3 Enzyme activities of legumain (A), cathepsin B (B) and
cathepsin L (C) in various cell lines. Whole cell extracts from
common laboratory non-melanoma and established laboratory
melanoma cell lines, primary and metastatic melanoma cell lines
established from patients, and skin cell controls were collected 24 h
after seeding. Legumain (A), cathepsin B (B) and L (C) activities in
each cell lysate were measured by cleavage of peptide substrates
and fluorometry (see Materials and methods for details). Note: The
Y-axis in A and B are shown as dF/μg total protein whereas y-axis in
C is shown as log dF/μg total protein.
Figure 4 Cystatin E/M over-expression in melanoma cells
suppressed legumain activity: A375 and MCC11 cells were
transfected with pCST6 (closed bars) or empty pTracer vector
(control; open bars), media were changed the following day, and
serum-free conditioned media and cell lysates were collected 24 h
later. (A) Immunoblots of cystatin E/M in conditioned media (CM)
and lysates. Secreted proteins were TCA-precipitated prior to SDS-
PAGE and immunoblotting. The filters were stained with a cystatin
E/M-specific (upper and middle panels) or a b-actin specific (lower
panel; loading control) antibody, respectively. (B) Inhibitory activity
against legumain was measured in the conditioned media as
residual legumain activity using fluorometry, a fixed amount of
partially purified legumain from rat kidney and the substrate Z-Ala-
Ala-Asn-NHMec (A375, p < 0.0001; MCC11, p = 0.002). (C) Activity of
legumain in cell lysates measured by cleavage of Z-Ala-Ala-Asn-
NHMec (A375, p < 0.0001; MCC11, p = 0.0012). Error bars represent
the standard error of the mean (SEM).
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of a transwell plate. Invasion was significantly decreased
by 39% in A375 (p < 0.01) and 41% (p < 0.05) in
MCC11 following transfection with pCST6 (Fig. 5). In
contrast, there was no change in the rate of growth or
motility when transwell plates without Matrigel were
utilized (data not shown).
Discussion
In this study, we provide data indicating that cystatin
E/M suppresses invasiveness of melanoma cells, likely
via the inhibition of the cysteine protease legumain
known to be present in metastatic lesions. We have
observed expression of cystatin E/M, legumain, cathe-
psin B and L in multiple melanoma cell lines, and an
inverse correlation between secreted levels of the
cysteine protease inhibitor and cellular activities of legu-
main and cathepsin B (but not cathepsin L) was
detected. When cells lacking cystatin E/M were trans-
fected with an expression vector containing cystatin E/
M cDNA (pCST6), a significant decrease in cellular
legumain activity was observed, and conditioned media
collected from the transfected cells had high inhibitory
activity against exogenously added legumain. Further-
more, following transfection with pCST6, invasiveness
was significantly decreased as measured in a Matrigel
invasion assay. Collectively, our data strongly suggests
that cystatin E/M inhibits melanoma progression by
suppressing legumain activity.
In a previous study comparing the gene expression
profiles of primary and metastatic melanoma, it was
shown that CST6 gene expression progressively
decreases during disease progression [31]. When mela-
nomas with intermediate Breslow’s tumor thickness
were compared to thick primary lesions, a substantial
(nearly 70-fold) decrease in CST6 gene expression was
observed. Furthermore, there was a significant decrease
in CST6 expression between primary and metastatic
melanoma when analyzed by microarray and quantita-
tive RT-PCR. These data were the first to suggest that
expression of CST6 decreases during progression to
metastatic melanoma, a finding that is in agreement
with previous studies in breast cancer [5].
We have identified several cell lines derived from both
primary and metastatic melanoma that secrete cystatin
E/M. However, despite data suggesting that cystatin
E/M has tumor suppressive capabilities, we did not
detect lower levels in the metastatic versus the primary
cell lines. This was probably due to the relatively small
number of cell lines at our disposal originating from pri-
mary tumors, and furthermore, that most of these lines
were derived from rather large lesions possibly having a
phenotype more closely resembling metastatic rather
than primary melanoma. Interestingly, the glycosylated
17 kD cystatin E/M form predominated in the mela-
noma samples, whereas the unglycosylated 14 kD form
predominated in HaCaT keratinocytes. To confirm that
CST6 functions as a tumor suppressor gene in mela-
noma, further studies are needed to determine the
extent of cystatin E/M expression and the glycosylation
status in cultured melanocytes and thin primary tumors.
Although the expression of cystatin E/M in melano-
cytes has not been demonstrated, it has previously been
shown that the protein is secreted from keratinocytes
and thus present within the tumor microenvironment of
the primary melanoma [49]. Herein, we show that cysta-
tin E/M is secreted by HaCaT keratinocytes, whereas no
cystatin E/M was observed in lysates of either melano-
cytes or HaCaT cells. In normal human skin, cystatin
E/M has been observed to be constitutively expressed in
the stratum granulosum, sweat glands, sebaceous glands
and hair follicles [49,50]. During inflammation, its
expression is detectable within several layers of the skin
and into the stratum spinosum. Interestingly, basal cell
and squamous cell carcinomas were found to express
cystatin E/M only in well differentiated cells. However,
there has been no histological examination of cystatin
E/M expression in nevi, melanoma in situ or primary
melanoma.
By immunoblotting, we detected cystatin E/M secre-
tion from four melanoma cell lines (MCC13, 57, 70 and
72), and the conditioned media from these cells demon-
strated the highest inhibitory activities against legumain.
Surprisingly, we detected cystatin E/M by ELISA in
media from only one of these melanoma cell lines.
There are several potential explanations for this discre-
pancy, but the most likely being that there are funda-
mental differences between the applied methods.
Immunoblotting measures denatured proteins while the
ELISA attempts to detect the native cystatin E/M,
Figure 5 Over-expression of cystatin E/M suppressed
melanoma cell invasion. A375 and MCC11 cells were transfected
with pCST6 (closed bars) or empty vector (control; open bars) and
migration through Matrigel coated transwell membranes was
determined. The bars represent the average of four or three
experiments for A375 and MCC11, respectively, with six replicate
wells for each transfection group (A375, p < 0.01; MCC11, p < 0.05).
Error bars represent the standard error of the mean (SEM).
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possibly in complex with the interacting proteases. It is
also possible that the amount of cystatin E/M in the
media collected from the melanoma lines is below the
limit of detection in the ELISA assay, as some cell lines
showing strong expression on immunoblotting (e.g.
HCT-116, MA11) had low amounts detected by ELISA.
Furthermore, we utilized different antibodies in the two
assays in this study and differences in the antibody affi-
nity for the various forms of cystatin E/M are probable.
The polyclonal antiserum used in the ELISA has, how-
ever, been demonstrated to recognize both the glycosy-
lated and non-glycosylated forms of cystatin E/M (data
not shown), making this explanation less likely. Never-
theless, there was a statistical positive correlation
between the ELISA results for cystatin E/M and both
molecular forms observed by immunoblotting.
Some interesting relationships were observed between
the different expression profiles of cystatin E/M, cystatin
C, legumain, cathepsin B and L. First, in most mela-
noma cell lines examined, we identified an inverse cor-
relation between secreted cystatin E/M and C. The only
exception was the ocular melanoma cell line 92.1, in
which neither of the cystatin isoforms was detected.
Likewise, a similar inverse correlation between secreted
cystatin E/M and both pro- and active forms of the
examined proteases in lysates was observed. Legumain
was expressed at very low levels in cell lines secreting
cystatin E/M (MCC13, MCC70, MCC57 and MCC72),
while immunobands representing active legumain were
high in all cells lacking the protease inhibitor. Similarly,
with one exception (MCC70), there was no detectable
expression of neither cathepsin B or L in the cells
secreting cystatin E/M. Interestingly, this pattern was
observed only in the melanomas and not in the cell
lines derived from other cancer types. Although the
expression levels of cystatin E/M and the proteases
inversely correlated, an alternative explanation could be
that cystatin E/M and protease expression levels are
counter-regulated by some unknown mechanism. If so,
the lower metastatic potential of the cystatin E/M
expressing cells might be due to lower total expression
levels of legumain, cathepsin B and L, respectively, and
should be investigated further.
Although legumain has been shown to impart metastatic
properties in several different types of cancer, the present
study is the first to address the expression and activity of
the protease in melanoma. In general, high legumain
expression and activity was revealed in the examined
panel of melanoma cell lines. Two immunobands were
repeatedly observed, one migrating at approximately 52
kD corresponding to the inactive proform of the enzyme,
and the other at approximately 36 kD corresponding to
the active form [51]. The latter form was observed in the
majority of the melanoma cell lines, and the intensity of
this band correlated significantly with legumain activity in
each cell line. Moreover, legumain has been shown to be
involved in processing and activation of proteases such as
cathepsin L [52]. In our study, comparisons of band inten-
sities of legumain and cathepsin L did not statistically cor-
relate, but the melanoma cell lines derived from patient
biopsies seemed to express a stronger 25 kD mature cathe-
psin L immunoband in the cell lines with a strong 36 kD
active legumain band.
To determine the influence of cystatin E/M on protease
activity and invasion, two cell lines (A375 and MCC11)
with no basal secretion of cystatin E/M were transfected
with pCST6. Cystatin E/M over-expression resulted in sig-
nificantly increased ability to inhibit exogenously added
legumain by the conditioned media, as well as decreased
cellular legumain activity. The percentage decrease in
legumain activity was greater in lysates from A375 than
MCC11, possibly due to the lower basal level of legumain
activity in A375. Surprisingly, cathepsin B was not affected
by over-expression of cystatin E/M in these cells. Further-
more, a significant inhibition of invasive capacity was
observed in both cell lines following transfection with
pCST6. Since enhanced expression of cystatin E/M did
not influence on the cell ability to migrate, the observed
effect on invasion is most likely due to cystatin E/M-
mediated inhibition of legumain activity. However, it is
possible that the decreased invasiveness could in part
result from effects on proteases other than legumain.
Although the majority of reports on cystatin E/M have
indicated that it suppresses tumor growth and metasta-
sis, there have been some conflicting data regarding the
role of the protease inhibitor in cancer. It has been
reported that cystatin E/M is up-regulated during the
progression from primary to metastatic oropharyngeal
squamous cell carcinoma [53]. In addition, silencing of
cystatin E/M markedly increased proliferation rate, in
vitro motility and Matrigel invasiveness [54]. A study in
pancreatic cancer showed that knockdown of cystatin
E/M with siRNA suppressed in vitro growth whereas
over-expression increased growth rate and tumor bur-
den in vivo in pancreatic cancer [55]. The authors pro-
posed that the growth enhancing properties of cystatin
E/M result from inhibition of cathepsin B facilitated
apoptosis. However, we could not detect any changes in
cathepsin B activity when over-expressing cystatin E/M
in melanoma cells. Despite these reports, the majority of
studies in other tumor types have found that cystatin E/
M exerts a suppressive effect on carcinogenesis and
demonstrated growth and metastasis suppressing prop-
erties in both breast cancer and glioma [12-14].
Conclusions
In summary, we have shown that cystatin E/M acts as a
regulator of proteolytic activity of legumain and
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suppressor of invasion in metastatic melanoma. Further
studies are needed to elucidate the role of both cystatin
E/M and legumain in melanoma, including their expres-
sions during different stages of the disease and their
roles in tumor formation and metastasis in vivo. The
data presented provide new insight into the role of
cystatin E/M in protease regulation and invasion in
malignant melanoma.
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